ClinicalTrials.gg
CompletedNCT07257549Updated Oct 22, 2026

Real-Time Non-Invasive Localization for Multiple Lung Nodules

An interventional study of Manual needle localization and Real-time non-invasive localization in Lung Cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 22, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.

Enrollment
9th of 18
120 · median 110
Started
2025
with 7 others
No phase
12 of 26
9 open now
Registered
22nd of 26
by date

Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 8 that started in 2025, is one of 12 with no phase, and was the 22nd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, or all of them as a file.
02

Study summary

This study compares real-time non-invasive localization and manual CT-guided needle localization for multiple lung nodules under 20 mm. It primarily aims to evaluate the successful resection rate of pulmonary nodules.

Read the detailed description

This is a prospective, single-center, non-inferiority clinical study designed to evaluate the effectiveness of a real-time non-invasive localization. The study will be conducted between December 2025 to July 2026, involving 120 patients with multiple lung nodules smaller than 20 mm in diameter. Participants will be randomly assigned to receive either CT-guided manual needle localization or real-time non-invasive localization. The primary outcome measure will be the successful resection rate of pulmonary nodules. Secondary outcome measures will include resection margins, changes in operative approach, intraoperative blood loss, operative time, postoperative hospitalization days, the placement of chest tubes, the duration of chest tube placement, and postoperative complications.

03

Conditions studied

  • Lung Cancer (NSCLC)

Keywords

  • Preoperative localization
  • lung nodule
  • lung cancer
  • Video-assisted thoracic surgery
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. the maximum diameter of the lesion on CT did not exceed 20 mm;
  2. at least two pulmonary nodules identified;
  3. pulmonary nodules showed pure ground-glass opacity (GGO) or mixed GGO on imaging;
  4. the outer edge of nodules located between 5-20 mm from the nearest pleural surface.

Exclusion criteria

Exclusion Criteria:

  1. nodule location obstructed by the scapula, precluding needle access;
  2. proximity of the nodule to major blood vessels, defined as within 2 cm;
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Non-invasive group

    Real-time non-invasive localization of multiple pulmonary nodules

    Procedure: Real-time non-invasive localization

  • Active comparator
    CT-guided group

    Manual CT-guided percutaneous needle localization of multiple pulmonary nodules

    Procedure: Manual needle localization

Interventions

  • ProcedureManual needle localization

    Manual needle localization involves the traditional technique of percutaneous localization of pulmonary nodules under CT guidance. The procedure is performed by the physician manually guiding the needle based on real-time CT imaging. The physician adjusts the needle position based on visual cues from the CT scan, which may require multiple attempts for accurate localization. After confirming the needle tip's proximity to the target nodule, indocyanine green (ICG) was injected during deep inspiration to mark the nodule for intraoperative fluorescence imaging. The thoracic surgeon completed resection of the pulmonary nodule based on the area delineated by ICG.

  • ProcedureReal-time non-invasive localization

    The patient underwent a CT scan prior to surgery. The acquired CT image data was saved in DICOM format and subsequently imported into software for three-dimensional reconstruction of the lung lobes, blood vessels, and bronchi. During the procedure, an assistant created a three-dimensional lung model on a separate monitor, aligning it roughly with the orientation of the deflated lung observed via thoracoscopy. The thoracic surgeon then completed resection of the pulmonary nodule guided by the surgeon's three-dimensional lung model.

06

What researchers measure

Primary outcomes

  1. The successful resection of all planned target nodules per patient

    The primary outcome of this study was the successful resection of all planned target nodules per patient. A lesion was considered successfully resected if the surgical margin was equal to or greater than either the lesion diameter or 2 cm. Generally, after intraoperative resection of the lesion, the margin length was verified by direct measurement on the resected deflated lung specimen. If macroscopic measurement of the surgical margin was challenging, the distance from the nodule to the marker was assessed using intraoperative frozen section analysis. Additionally, any change in surgical approach resulting from unsuccessful nodule localization was considered a failure of lesion resection, regardless of margin size.

    Time frame: Day of surgery.

Secondary outcomes

  1. Resection margins

    Distance from the nodule to the resection margin

    Time frame: Day of surgery.

  2. Changes in operative approach

    During surgery, the planned approach must be changed when the target nodule cannot be completely resected due to various reasons.

    Time frame: Day of surgery.

  3. Intraoperative blood loss

    Hemorrhage during surgery.

    Time frame: Day of surgery.

  4. Operative time

    Total duration of the thoracic surgical procedure, measured in minutes from skin incision to completion of skin closure for the index operation.

    Time frame: Day of surgery.

  5. Postoperative hospitalization days

    The postoperative hospitalization duration refers to the total number of days the patient remains in the hospital from the completion of surgery until discharge.

    Time frame: Perioperative.

  6. The placement of chest tubes

    Determine whether a chest tube needs to be placed based on the patient's condition during surgery.

    Time frame: Day of surgery.

  7. The duration of chest tube placement

    The chest tube placement duration refers to the number of days from the placement of the chest tube after surgery until its removal.

    Time frame: Perioperative.

  8. Postoperative complications

    Postoperative complications refer to any adverse events or symptoms that occur after surgery.

    Time frame: Perioperative.

07

Study locations

1 site
  • The First Affiliated of Guangzhou Medical University
    Guangzhou, Guangdong, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jul 2026, 7 months.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 7 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Jul 2024 → Dec 2025, primary completion May 2025 → Jul 2026 and completion Jul 2025 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 2, 2025
StartActual
Dec 1, 2025was Jul 2024
Primary completionActual
Jul 1, 2026was May 2025
CompletionActual
Jul 1, 2026was Jul 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2024→Dec 1, 2025
Oct 22, 2026
Primary completion
May 1, 2025→Jul 1, 2026
Oct 22, 2026
Study completion
Jul 1, 2025→Jul 1, 2026
Oct 22, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • Removedrequirement for localization of multiple pulmonary nodules.
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Jul 1, 2024→Dec 1, 2025
    Primary completion May 1, 2025→Jul 1, 2026
    Study completion Jul 1, 2025→Jul 1, 2026
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • Removedrequirement for localization of multiple pulmonary nodules.
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07257549
Responsible party
Jianxing He (Professor, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Dec 2, 2025
Start date
Dec 1, 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion